[Skip to Content]
[Skip to Content Landing]
Citations 0
The World in Medicine
December 15, 2004

Vioxx Controversy

JAMA. 2004;292(23):2827. doi:10.1001/jama.292.23.2827-a

Rofecoxib (Vioxx) should have been withdrawn from the market 4 years ago because there was sufficient evidence at that time that the drug raised the risk of myocardial infarction, a team of researchers from Switzerland and the United Kingdom concluded in a November 5 online edition of the Lancet (http://www.thelancet.com). Merck & Co Inc, the drug’s manufacturer, had announced on September 29 that it was withdrawing the drug, a selective cyclooxygenase 2 (COX-2) inhibitor, from the market.

First Page Preview View Large
First page PDF preview
First page PDF preview